Synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
Methods, pharmaceutical formulations, and kits are provided for using Transient Receptor Potential Vanilloid 1 (TRPV1) agonists to increase rectal pressure and induce defecation in mammals.
A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
C07C 275/24 - Dérivés d'urée, c.-à-d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles aromatiques à six chaînons
C07C 275/36 - Dérivés d'urée, c.-à-d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant des atomes d'azote de groupes urée et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec au moins un des atomes d'oxygène lié de plus à un atome de carbone d'un cycle aromatique à six chaînons, p. ex. N-aryloxyphénylurées
3.
COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION
Synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary "on-demand" voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C07D 207/00 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle
4.
COMPOSITIONS AND METHODS FOR TREATING AUTONOMIC DYSREFLEXIA
Compositions and methods are provided to treat, prevent and/or reduce the frequency of autonomic dysreflexia (AD) and/or episodic hypertensive events. The compositions include NK1 receptor antagonists for parenteral or enteral administration to a subject, or pharmaceutically acceptable salts, esters, amides, prodrugs, or derivatives thereof. The NK1 receptor antagonists can selectively block activation of NK1 receptors in the peripheral and central nervous system that give rise to AD. Methods are provided for treating an acute episode of AD in a subject by parenterally administering a therapeutically effective amount of a NK1 receptor antagonist to reduce the severity and/or duration of the AD. In addition, methods are provided for preventing or reducing the frequency and/or severity of AD by administering either parenterally or enterally a therapeutically effective amount of a NK1 receptor antagonist to a subject on a continuous basis, such as twice daily, once daily, or once weekly.
Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.
Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.
Eleven synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
A stimulator device for controlling waste storage for a subject, having one electrode placed in proximity to a portion of each of the right and left pudendal nerves, which contains efferent fibers that, when stimulated, produce contraction of the urethral or anal sphincter. The stimulator device having a pulse generator connected to electrodes, bilaterally, to provide stimulation for each electrode to stimulate pudendal efferent axons. The pulse generator adapted to provide a first type of stimulation to cause waste to be stored within the subject. The pulse generator adapted to provide a second type of stimulation, different from the first type of stimulation, to allow waste to be voided from the subject by blocking nerve impulses that accompany sphincter dyssynergia. An input device to allow an end user to select the first type of stimulation, the second type of stimulation, or no stimulation. Variations of the concept are disclosed.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A stimulator device for use in controlling waste storage for a patient. The stimulator device having a set of at least one electrode placed in proximity to a relevant portion of a pudendal nerve. The stimulator device having a pulse generator connected to the set of at least one electrode to provide stimulation input for use by the electrode to stimulate the pudendal nerve. The pulse generator adapted to provide a first type of stimulation to cause waste to be stored within the patient and to provide a second type of stimulation different from the first type of stimulation. The second type of stimulation allows waste to be voided from the patient by blocking nerve impulses that would produce sphincter dyssynergia. An input device to allow an end user to select to apply the first type of stimulation or the second type of stimulation. Variations are also disclosed.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
Eleven synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary "on-demand" voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with voiding dysfunction control over when and where they void.
brevets
